Navigation Links
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Date:10/31/2007

nd Drug Administration ("FDA") or Acura's demonstration of certain stability and pharmacokinetic characteristics for each future product. All products developed pursuant to the Agreement will be manufactured by King or a third party contract manufacturer under the direction of King. Subject to the Agreement, King will have final decision making authority with respect to all development and commercialization activities for all products licensed.

The Agreement closing is subject to antitrust review under the Hart-Scott- Rodino Antitrust Improvements Act.

The United States Patent and Trademark Office has granted U.S. Patent No. 7,201,920 relating to Acura's Aversion(R) (abuse-deterrent) Technology, which expires on March 16, 2025.

About ACUROX(TM) Tablets

ACUROX(TM) (formerly OxyADF) is an orally administered immediate release tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. ACUROX(TM) Tablets are intended to effectively treat moderate to moderately severe pain while discouraging the three most common methods of prescription drug abuse including (i) intravenous injection of dissolved tablets, (ii) nasal snorting of crushed tablets and (iii) intentional swallowing of excessive numbers of tablets.

Earlier this year, Acura reached agreement with the FDA on a Special Protocol Assessment for a pivotal Phase 3 clinical trial evaluating ACUROX(TM) Tablets. This clinical trial is a randomized, double-blind, placebo- controlled, multi-center, repeat-dose study evaluating the safety and efficacy of ACUROX(TM) Tablets for the treatment of acute, moderate to moderately severe postoperative pain. The 3-arm clinical trial compares two dose levels of ACUROX(TM) Tablets to placebo and is targeted to enroll 135 patients per arm (approximately 405 patients in total). Study medication will be administered to patients every six hours for
'/>"/>

SOURCE King Pharmaceuticals, Inc.; Acura Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... new computer program could help doctors predict which patients ... treatment. , The program, which assesses brain scans ... airport security and passport control, has been developed by ... study funded by the Wellcome Trust, which used the ... . , Stroke affects over 15 million people ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... study found, , , WEDNESDAY, Feb. 11 (HealthDay News) -- Offering ... their unhealthy habit helps more people give up cigarettes, new ... issue of the New England Journal of Medicine , ... the country who were offered up to $750 to give ...
... 11 St. Mary-Corwin Medical Center joins Centura ... observe Heart Month throughout the month of February. ... consumer promotions to provide southern Colorado communities with ... the leading cause of death among Coloradans.Centura has ...
... Down from 2005 ProjectionsHARRISBURG, Pa., Feb. 11 The ... part, because of the efforts of the Pennsylvania Center ... Secretary Sandi Vito announced today. The information is included ... Nurse Workforce in Pennsylvania " and " The Licensed ...
... today by AARP Pennsylvania: WHO: AARP will host ... WHAT: Participants will express their views on how ... communities. And, they will hear from Senator Specter on ... problems under a new Administration and Congress. WHEN: ...
... have identified a new biological marker present in the ... the cancer is progressing and spreading. , In experiments ... journal Nature, the scientists identified 10 metabolites ... progresses. Their studies showed that one of these chemicals, ...
... of Generation-X say they feel unprepared for long-term care ... steps to prepare for their futures, according to a ... The survey, conducted by StrategyOne on behalf of AHIP, ... between 1960 and 1980 feel somewhat or entirely unprepared ...
Cached Medicine News:Health News:Promise of Cash Prompts Smokers to Quit 2Health News:Promise of Cash Prompts Smokers to Quit 3Health News:St. Mary-Corwin Medical Center and Centura Health Celebrate Heart Month 2Health News:St. Mary-Corwin Medical Center and Centura Health Celebrate Heart Month 3Health News:Work of PA Center for Health Careers Eases Pennsylvania's Nursing Shortage 2Health News:Survey of metabolites finds new prostate cancer marker 2Health News:Survey of metabolites finds new prostate cancer marker 3Health News:Generation-X Feels Unprepared for Long-Term Care Costs and the Future, Survey Finds 2Health News:Generation-X Feels Unprepared for Long-Term Care Costs and the Future, Survey Finds 3
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
Ralk Hand Drill, with Jacobs chuck, wrench-locking, with axial channel for Kirschner wires, for twist drills up to 7 mm , for Kirschner wires up to 4 mm...
DeMartel (Bailey) Wire Saw Guide, 33 cm - 13, flexible....
Hudson brace only. Component parts and accessories for Hudson cranial drill....
23 cm - 9, adult size, for skull thickness up to 12 mm....
Medicine Products: